183 related articles for article (PubMed ID: 28670847)
1. Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
Chen H; Na R; Packiam VT; Conran CA; Jiang D; Tao S; Yu H; Lin X; Meng W; Zheng SL; Brendler CB; Helfand BT; Xu J
Prostate; 2017 Aug; 77(11):1179-1186. PubMed ID: 28670847
[TBL] [Abstract][Full Text] [Related]
2. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
[TBL] [Abstract][Full Text] [Related]
3. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
Conran CA; Na R; Chen H; Jiang D; Lin X; Zheng SL; Brendler CB; Xu J
Asian J Androl; 2016; 18(4):520-4. PubMed ID: 27080480
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial.
Milonas D; Auskalnis S; Skulcius G; Gudinaviciene I; Jievaltas M; Joniau S
World J Urol; 2017 May; 35(5):721-728. PubMed ID: 27644229
[TBL] [Abstract][Full Text] [Related]
5. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
6. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
[TBL] [Abstract][Full Text] [Related]
7. Clinical validity and utility of genetic risk scores in prostate cancer.
Helfand BT; Kearns J; Conran C; Xu J
Asian J Androl; 2016; 18(4):509-14. PubMed ID: 27297129
[TBL] [Abstract][Full Text] [Related]
8. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.
Na R; Ye D; Qi J; Liu F; Lin X; Helfand BT; Brendler CB; Conran C; Gong J; Wu Y; Gao X; Chen Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
Asian J Androl; 2016; 18(4):525-9. PubMed ID: 27140652
[TBL] [Abstract][Full Text] [Related]
9. Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment.
Yu H; Shi Z; Lin X; Bao Q; Jia H; Wei J; Helfand BT; Zheng SL; Duggan D; Lu D; Mo Z; Xu J
Prostate; 2020 Jan; 80(1):83-87. PubMed ID: 31634418
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
Sciarra A; Maggi M; Fasulo A; Salciccia S; Gentile V; Cattarino S; Gentilucci A
Urologia; 2017 Aug; 84(3):158-164. PubMed ID: 28430341
[TBL] [Abstract][Full Text] [Related]
12. Assessing the clinical utility of genetic risk scores for targeted cancer screening.
Conran CA; Shi Z; Resurreccion WK; Na R; Helfand BT; Genova E; Zheng SL; Brendler CB; Xu J
J Transl Med; 2021 Jan; 19(1):41. PubMed ID: 33482857
[TBL] [Abstract][Full Text] [Related]
13. Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.
Ren S; Xu J; Zhou T; Jiang H; Chen H; Liu F; Na R; Zhang L; Wu Y; Sun J; Yang B; Gao X; Zheng SL; Xu C; Ding Q; Sun Y
Prostate; 2013 Dec; 73(16):1824-35. PubMed ID: 24037738
[TBL] [Abstract][Full Text] [Related]
14. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.
Wilt TJ; Macdonald R; Hagerty K; Schellhammer P; Tacklind J; Somerfield MR; Kramer BS
BJU Int; 2010 Nov; 106(10):1444-51. PubMed ID: 20977593
[TBL] [Abstract][Full Text] [Related]
15. The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
Jamnagerwalla J; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
J Urol; 2016 Sep; 196(3):715-20. PubMed ID: 27060053
[TBL] [Abstract][Full Text] [Related]
16. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
17. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
Sun J; Kader AK; Hsu FC; Kim ST; Zhu Y; Turner AR; Jin T; Zhang Z; Adolfsson J; Wiklund F; Zheng SL; Isaacs WB; Grönberg H; Xu J
Prostate; 2011 Mar; 71(4):421-30. PubMed ID: 20878950
[TBL] [Abstract][Full Text] [Related]
18. [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA].
Endo T; Kamiya N; Yano M; Oka R; Lee FC; Utsumi T; Kamijima S; Nishimi D; Takanami M; Hiruta N; Suzuki H
Nihon Hinyokika Gakkai Zasshi; 2015 Jul; 106(3):156-62. PubMed ID: 26419072
[TBL] [Abstract][Full Text] [Related]
19. Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.
Ahmed M; Goh C; Saunders E; Cieza-Borrella C; ; Kote-Jarai Z; Schumacher FR; Eeles R
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):333-342. PubMed ID: 31776447
[TBL] [Abstract][Full Text] [Related]
20. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
